Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
The Genes and Cancer Group at the Cancer Epigenetics and Biology Program of the IDIBELL has found that the MAX gene, which encodes a partner of the MYC oncogene, is genetically inactivated in small cell lung cancer. Reconstitution of MAX significantly reduced cell growth in the MAX-deficient cancer cell lines. These findings show that MAX acts as a tumor suppressor gene in one of the more aggressive types of lung cancer.
In addition to identifying the tumor suppressor role of MAX in lung cancer, the group led by Montse Sanchez-Cespedes has unveiled a functional relationship between MAX and another tumor suppressor, BRG1, in virtue of which BRG1 regulates the expression of MAX through direct recruitment to the MAX promoter. However, the functional connection is even more complex. On one hand, the presence of BRG1 is required to activate neuroendocrine transcriptional programs and to up-regulate MYC-targets, such as glycolytic-related genes. Moreover, the depletion of BRG1 strongly hinders cell growth, specifically in MAX-deficient cells, heralding a synthetic lethal interaction. The preferential toxicity of the inactivation of BRG1 in MAX-deficient lung cancer cells opens novel therapeutic possibilities for the treatment of SCLC patients with MAX-deficient tumors.
The Genes and Cancer group has identified several genes altered in lung cancer. Among these is BRG1 (also called SMARCA4) and the latest generation-sequencing technologies have extended these findings to other tumor types evidencing that BRG1 inactivation is widespread in cancer. BRG1 encodes one ATPase of the SWI/SNF chromatin remodeling complex and Dr. Sanchez-Cespedes group had previously shown that loss of BRG1 is closely related to the activation of MYC in lung cancer. Both conditions are mutually exclusive and act preventing cell differentiation and promoting cell growth. The current discovery that MAX acts as a tumor suppressor in lung cancer provides evidence that an aberrant SWI/SNF-MYC/MAX network is essential for lung cancer development.
Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M. MAX inactivation in small-cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov. 2013 Dec 20. [Epub ahead of print]. doi: 10.1158/2159-8290.CD-13-0799.
Romero OA, Sanchez-Cespedes M. The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases. Oncogene. 2013 Jun 10. [Epub ahead of print]. doi:10.1038/onc.2013.227.
Romero OA, Setien F, John S, Gimenez-Xavier P, Gómez-López G, Pisano D, Condom E, Villanueva A, Hager GL, Sanchez-Cespedes M. The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer.EMBO Mol Med. 2012 Jul;4(7):603-16. doi: 10.1002/emmm.201200236
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Lung Cancer category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
IDIBELL-Bellvitge Biomedical Research Institute. "A tumor suppressor gene discovered in a very aggressive lung cancer." Medical News Today. MediLexicon, Intl., 13 Jan. 2014. Web.
9 Mar. 2014. <http://www.medicalnewstoday.com/releases/271056>
IDIBELL-Bellvitge Biomedical Research Institute. (2014, January 13). "A tumor suppressor gene discovered in a very aggressive lung cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271056.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.